How MS treatment performs beyond clinical trials. What happens when a high efficacy MS therapy is tested in real patients across years of routine care?
End of Content.
Get the latest creative news from us about politics, business, sport and travel
End of Content.
Ethel Ciampi is an Associate Professor at the Pontificia Universidad Católica de Chile. She completed training in MS and demyelinating disorders at CEMCAT, holds a Neuroimmunology Master's, and has advanced clinical research training from Harvard. She co-directs the MS and Neuroimmunology Fellowship at PUC and leads the Neuroimmunology Unit at Hospital Dr. Sótero del Río. Her research focuses on real-world evidence and healthcare access disparities in Latin America. With over 80 publications and as Co-Chair of the Global Epidemiology group for iWiMS and medical advisor for The Mog Project, her goal is to improve patient quality of life through evidence-based decisions and advocacy.

Ethel Ciampi is an Associate Professor at the Pontificia Universidad Católica de Chile. She completed training in MS and demyelinating disorders at CEMCAT, holds a Neuroimmunology Master’s, and has advanced clinical research training from Harvard. She co-directs the MS and Neuroimmunology Fellowship at PUC and leads the Neuroimmunology Unit at Hospital Dr. Sótero del Río. Her research focuses on real-world evidence and healthcare access disparities in Latin America. With over 80 publications and as Co-Chair of the Global Epidemiology group for iWiMS and medical advisor for The Mog Project, her goal is to improve patient quality of life through evidence-based decisions and advocacy.
How MS treatment performs beyond clinical trials. What happens when a high efficacy MS therapy is tested in real patients across years of routine care?